An Open-Label Trial of Aripiprazole Treatment in Dual Diagnosis Individuals: Safety and Efficacy

    Authors

    A. L. McRae-Clark; M. L. Verduin; B. K. Tolliver; R. E. Carter; A. E. Wahlquist; K. T. Brady; J. S. Cluver;S. Anderson

    Comments

    Authors: contact us about adding a copy of your work at STARS@ucf.edu

    Abstract

    This open-label study evaluated the safety and efficacy of aripiprazole in the treatment of 20 patients with co-morbid schizophrenia, schizoaffective disorder, or bipolar disorder and alcohol, cocaine, and/or marijuana use disorders. Primary outcomes were substance use, measured by the Timeline Followback, and score on the Clinical Global Impression scale for psychiatric and substance use symptoms. The data suggest that aripiprazole may reduce substance use and improve psychiatric symptoms in patients with co-morbid disorders; however, limitations are noted. Subsequent randomized studies are needed to further explore these findings.

    Journal Title

    Journal of Dual Diagnosis

    Volume

    5

    Issue/Number

    1

    Publication Date

    1-1-2009

    Document Type

    Article

    First Page

    83

    Last Page

    96

    WOS Identifier

    WOS:000283303200007

    ISSN

    1550-4263

    Share

    COinS